این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Iranian Heart Journal، جلد ۲۶، شماره ۱، صفحات ۵۴-۶۶
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی The Relationship Between High-Dose Atorvastatin Loading and the No-Reflow Phenomenon in STEMI Patients Undergoing Primary PCI
چکیده انگلیسی مقاله Background: Percutaneous coronary intervention (PCI) is the preferred reperfusion strategy for acute coronary syndrome. However, no-reflow can still occur and is associated with worse in-hospital and long-term prognoses. This study aims to assess the impact of high-dose atorvastatin loading before primary PCI on ST-elevation myocardial infarction (STEMI) patients with no-reflow and major adverse cardiovascular events (MACE) after 1 month.   Methods: Two hundred STEMI patients undergoing primary PCI were allocated and randomized into 2 groups: the study group received high-intensity statin (80 mg of atorvastatin) in addition to guideline-recommended therapy before primary PCI, while the control group received guideline-recommended therapy before primary PCI. Angiographic and echocardiographic assessments were thoroughly conducted for both groups.   Results: No significant differences in demographic data were observed between the 2 groups. A significant decrease in the no-reflow phenomenon was seen in the study group compared with the control group (28% vs 47%; P = 0.006). Moreover, a better myocardial blush grade was noted in the study group (0–1: 28% vs 43% and 2–3: 72% vs 57%; P = 0.027), along with a higher ejection fraction 24 hours after PCI (mean ± SD = 48.35 ± 8.78 vs 45.20 ± 7.89; P = 0.008) and improved ejection fraction after 1 month (43% vs 20%; P = 0.039). Nonetheless, no significant impact on MACE was found after 1 month.   Conclusions: High-dose atorvastatin loading before primary PCI led to improvements in postprocedural myocardial blush grade, the no-reflow phenomenon, and ejection fraction (both after 24 hours and 1 month). Still, no significant reduction in MACE was observed after 1 month. Despite this, our findings support the routine use of high-dose atorvastatin before primary PCI in patients presenting with STEMI. (Iranian Heart Journal 2025; 26(1): 54-66)
کلیدواژه‌های انگلیسی مقاله High-dose atorvastatin,No-reflow,STEMI,PCI
نویسندگان مقاله Bassam S. Hennawy |
Department of Cardiology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Amr Mohammed |
National Heart Institute, Cairo, Egypt.

Khaled A Fouad |
Department of Cardiology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

نشانی اینترنتی https://journal.iha.org.ir/article_212299_9435e554133305b0685bf1082f973460.pdf
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات